Ignite Creation Date:
2024-05-06 @ 6:58 PM
Last Modification Date:
2024-10-26 @ 2:58 PM
Study NCT ID:
NCT05848310
Status:
RECRUITING
Last Update Posted:
2024-02-29
First Post:
2023-04-28
Brief Title:
Preoperative Serum FGF19 in the Prognosis of Biliary Atresia
Sponsor:
Childrens Hospital of Fudan University
Organization:
Childrens Hospital of Fudan University
Study Overview
Official Title:
Preoperative Serum FGF19 in the Prognosis of Biliary Atresia
Status:
RECRUITING
Status Verified Date:
2024-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To investigate the role of preoperative serum FGF19 level in the prognosis of biliary atresia
Detailed Description:
Kasai portoenterostomy is currently one of the main treatment methods for biliary atresia but about 30 of children still require liver transplantation even after receiving the surgery Accurate prognosis will help select the most suitable treatment method for children but there is currently a lack of effective preoperative predictive indicators Serum FGF19 has recently been considered a possible preoperative predictive indicator for biliary atresia but its predictive value has not been confirmed in a large sample and in Asian population thus the investigators try to further explore the prognostic value of serum FGF19 in children with biliary atresia based on a large sample
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None